Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Oklahoma at trial's end says opioid 'kingpin' J&J fuelled epidemic

Published 15/07/2019, 17:34
Updated 15/07/2019, 17:36
Oklahoma at trial's end says opioid 'kingpin' J&J fuelled epidemic

By Heide Brandes

NORMAN, Okla. (Reuters) - Lawyers for the state of Oklahoma on Monday compared Johnson & Johnson (N:JNJ) to a drug cartel leader as they sought to hold the drugmaker responsible for fuelling the U.S. opioid epidemic in the first trial to result from lawsuits over the crisis.

Lawyers for the state, including Attorney General Mike Hunter, told a judge in Norman, Oklahoma that J&J's "greed" led the drugmaker to carry out a years-long marketing effort that caused "utter confusion" about the addictive painkillers' risks.

Brad Beckworth, a lawyer for the state, in his closing argument said J&J knew opioids were harmful, yet minimized their risk of addiction, resulting in a surge in overdose deaths as doctors overprescribed the drugs and they flooded the state.

"They didn't get here from a Mexican cartel," Beckworth said. "They got here from the pharmaceutical cartel, and the kingpin of them all is Johnson & Johnson."

Hunter, who sued J&J in 2017, said the New Brunswick, New Jersey-based company does not dispute the crisis exists, yet "they blame everyone but themselves."

The state urged Judge Thad Balkmanm, who presided over the nonjury trial for six weeks, to find J&J liable for creating a public nuisance and force it to pay up to $17 billion (£13.5 billion) over 30 years to address the epidemic.

J&J denies causing the epidemic. Its lawyers have argued that its products made up a small share of opioids prescribed in Oklahoma and carried U.S. Food and Drug Administration-approved labels that warned of the addictive risks.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The case is one of around 2,000 actions by state and local governments accusing drug manufacturers of contributing to the opioid epidemic. Opioids were linked to a record 47,600 overdose deaths in 2017, according to the U.S. Centers for Disease Control and Prevention.

The Oklahoma case is being closely watched by plaintiffs in other opioid lawsuits, particularly in 1,900 cases pending before a federal judge in Ohio who has been pushing for a settlement ahead of an October trial.

At trial, lawyers for Oklahoma argued that J&J, which sold the painkillers Duragesic and Nucynta, had since the 1990s marketed opioids as "safe and effective for everyday pain" while downplaying their addictive qualities.

Purdue and Teva Pharmaceutical (NYSE:TEVA) Industries Ltd (TA:TEVA) were originally also defendants in the case. Purdue reached a $270 million settlement with the state in March and Teva settled for $85 million in June. Both deny wrongdoing.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.